Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nutraceuticals vs. Conventional Therapy for Migraine
NCT07147972Phase 3Not yet recruiting
- Sponsor
- Fayoum University
- Start
- Aug 2025
- Primary completion
- Feb 2026
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Fayoum University. Primary endpoints: Migraine intensity (VAS score) at 3 months, Migraine duration at 3 months and 1 more. Planned start Aug 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT07147972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147972.